The Immunoadoptive Cell Therapy Private Limited (ImmunoACT), based in Mumbai, India, on October 13, 2023, announced the Central Drugs Standard Control Organization (CDSCO)’s approval for the use of the country’s first chimeric antigen receptor (CAR-T) cell therapy for the treating relapsed-refractory B-cell lymphoma and leukemia.
Trending
- Experts advocate digital health reform, say it reduces costs
- AMR: NCDC warns against indiscriminate sale of antibiotics
- African agricultural journalists elect new officials [MEET THE TEAM]
- Sokoto Muslims appreciate Buhari’s Ramadan support
- African agricultural journalists elect ASHENEWS’ Editor-in-Chief, El-Kurebe as PAAJ President
- Gombe farmers relocate to farms over escalating hippo attacks
- Power generation hits new peak of 5,713MW – TCN
- FG launches irrigation project in Bauchi to boost food security, economic growth
